What are your roles within GLIOMATCH?
Kathrin Cresswell leads the implementation science aspect of GLIOMATCH. Her team works on exploring implementation and adoption processes of the GLIOMATCH platform, including its scalability and long-term sustainability.
What challenges do scientists face when implementing new technology systems?
New technology systems are being developed constantly. The main problem is that most health information technology interventions – between 70 and 90% – fail because people don’t use them. This is due partly to that fact that these new technology systems sometimes create more work, disrupt organisational processes or are simply not deemed necessary to procure by the organisations that could use them. Other times, there might be existing health system factors that impede the implementation and adoption of these new technology systems.
How is GLIOMATCH working to address technology implementation challenges?
To mitigate the risks associated with known socio-technical challenges from the very beginning, the GLIOMATCH implementation science team is following a set framework rooted in social science. They conduct qualitative research through interviews and observations to analyse how the technology is being conceived and developed. Drawing on lessons from other biotech innovations, they work to understand the potentially unanticipated challenges of implementing GLIOMATCH. They also involve different stakeholders in the research, including patients, carers and healthcare professionals. This collaborative process is designed to increase the likelihood of the GLIOMATCH platform and associated information being adopted and used beyond the research project. Knowledge gained during the project will be compiled in a roadmap for consultation after the study.
What are the implementation goals for the GLIOMATCH platform?
The implementation science team is finding that there are many different visions of where GLIOMATCH can add value, but these differ significantly between interest holders and will likely emerge over long timeframes. Research and clinical applications have different pathways to impact and are interdependent. Real-world impacts are therefore emergent, but depend on stakeholder alignment across clinical, research, organisational, and commercial domains.
The final publication and video interview will be available on our website shortly.
In the meantime, we invite you to discover the rest of our GLIOMATCH: Explained series on our video page.




